CELLAVISION AB (publ) - Interim report for the period January 1 - March 31, 2010
(Thomson Reuters ONE) -
New distribution strategy provides enhanced growth opportunities
* Net sales amounted to SEK 21.1 million (22.0).
* The operating result was SEK -4.4 million (0.9).
* The result per share amounted to SEK -0.20 (0.02).
* Cash and cash equivalents amounted to SEK 18.0 million (14.5) by the end of
the quarter.
* CellaVision expanded its distribution network by entering a distribution
agreement with Beckman Coulter, and by extending its cooperation with
Sysmex.
* The Board of Directors of CellaVision plans to apply for a listing on NASDAQ
OMX Small Cap during the first half of 2010.
CellaVision in short
(MSEK) Q1 Q1 Full Year 2009
2010 2009
Net sales 21,1 22,0 109,0
Gross profit 14,0 14,1 76,5
Operating result -4,4 0,9 14,8
Result before tax -4,7 0,5 14,2
Cash flow -4,0 -5,2 2,3
CEO Comment
"We opened the year by introducing our new distribution strategy, which marks a
substantial shift in the distribution of our products. CellaVision signed a
distribution agreement with Beckman Coulter that came into effect on January 1,
while also concluding negotiations concerning an extended distribution agreement
with Sysmex. Both of these important agreements will be key in a new phase of
expansion - with two of the world's largest hematology companies, CellaVision
will be able to reach an even wider segment of the market. In 2010 we will be
focusing on increasing sales on our main markets in Europe, North America, and
Japan", says Yvonne Mårtensson, CEO of CellaVision.
"During the first quarter CellaVision allocated large resources to education and
support. We have managed to maintain a consistent level of expenses and gross
margin, however sales were somewhat slower compared to the same period the
previous year, as a consequense of the change in distribution strategy.
Development projects went on with intensity during the quarter but with no
capitalized costs. This makes a difference of 4.8 MSEK on the result compared to
last year.
"We will continue working on listing the CellaVision share on NASDAQ OMX
Stockholm, Small Cap, and aim to complete the process by the end of the
half-year. The listing will make CellaVision an even more attractive partner and
investment opportunity."
For more information please contact:
Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82,
e-mail:yvonne.martensson(at)cellavision.com
Johan Wennerholm, CFO. Phone: +46 708 33 81 68,
e-mail:johan.wennerholm(at)cellavision.com
Download the report by pressing the link below.
[HUG#1407092]
CellaVision AB - Interim report for the period January 1 - March 31, 2010: http://hugin.info/132164/R/1407092/360490.pdf
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 19570
Anzahl Zeichen: 0
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CELLAVISION AB (publ) - Interim report for the period January 1 - March 31, 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
